GlassScriptPhysician profile
Ralph B Hester
NPI 1215904974
$1,938.54
in general payments reported to CMS, 2019-2025
21 companies · $234 in 2025
The $234 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $631 · 2020: $232 · 2021: $187 · 2022: $142 · 2023: $83.22 · 2024: $429 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $746.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $257.44 | 2019-2024 | Cequa |
| Sight Sciences, INC. | $192.74 | 2019-2025 | Sion Surgical Instrument, Omni Surgical System |
| Kala Pharmaceuticals, INC. | $173.78 | 2019-2022 | |
| Harrow Eye, LLC | $141.18 | 2024-2025 | Vevye |
| Ocular Therapeutix, INC. | $114.98 | 2021-2024 | Dextenza |
| Johnson & Johnson Surgical Vision, INC. | $113.04 | 2019-2025 | Tecnis Iol |
| Bausch & Lomb Americas INC. | $107.24 | 2022-2025 | Vyzulta, Miebo, Prolensa |
| Shire North American Group INC | $96.84 | 2019 | |
| Aerie Pharmaceuticals, INC. | $95.84 | 2019-2021 | |
| Allergan, INC. | $92.79 | 2019-2021 | |
| Alcon Vision LLC | $85.36 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $79.64 | 2020-2021 | |
| The Cameron-Ehlen Group, INC. | $73.01 | 2019-2021 | |
| Rxsight INC | $72.45 | 2022-2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Novartis Pharmaceuticals Corporation | $68.83 | 2019-2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $44.53 | 2024 | Oxervate |
| Abbvie INC. | $44.47 | 2023-2025 | |
| Eyevance Pharmaceuticals LLC | $30.83 | 2019-2021 | |
| Glaukos Corporation | $22.22 | 2019 | |
| Oyster Point Pharma, INC. | $18.33 | 2025 | Ryzumvi, Tyrvaya |
| Clovis Oncology, INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Hester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.